Studio clinico 2026-526300-67-00 · Locally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III)
Ricerca oncologica
09/11/2026
2026-526300-67-00 — risulta «autorizzato» su CTIS (EU Clinical Trials Information System).
Studio clinico 2026-526300-67-00 (fase III) risulta «autorizzato» su CTIS (EU Clinical Trials Information System).
Patologia: Locally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III) · Interventi registrati: IMFINZI 50 mg/mL concentrate for solution for infusion, ivonescimab · Date registrate (fonte): 2026-11-06, 2026-11-08.
Fonte: https://euclinicaltrials.eu/ctis-public/view/2026-526300-67-00